The heart is the driving force of circulating blood in the body and pumps blood to the entire body by repeating contraction and relaxation of the heart muscles continuously. Human stem cells are used in the clinical therapies of a dead heart, which happens when a blood vessel is clogged or whole or a part of heart muscle is damaged. The clinical use of human bone marrow-derived mesenchymal stem cells (BM-MSCs) has been expanded but failure of the transplanted stem cells in the heart still remains a problem.
Recently, an international joint research team of POSTECH, Seoul St. Mary’s Hospital, and City University of Hong Kong developed a cardiac patch with bioink that enhanced the functionality of stem cells to regenerate blood vessels, which in turn improved the myocardial infarction affected area.
The research team mixed genetically engineered stem cells (genetically engineered hepatocyte growth factor-expressing MSCs, HGF-eMSCs) developed by SL Bigen Co., Ltd. to make bioink in the form of a patch and introduced a new therapy by transplanting it to a damaged heart. They called this new strategy in vivo priming (see figure). The name came from the principle that maximized function of mesenchymal stem cells is maintained in vivo as well as through its exposure to the growth factor secreted by the genetically engineered stem cells.
The joint research team first genetically engineered the existing BM-MSCs to produce hepatocyte growth factor consistently to improve the therapeutic potential of stem cells. The engineered stem cells (HGF-eMSCs) were then mixed with BM-MSCs to make the bioink. They transplanted the cardiac patch with this bioink to the heart muscles affected by myocardial infarction. Considering the limited amount of cells that could be transferred, they used heart-derived extracellular matrix bioink to make a cardiac patch.
Implanted cells in a patch survived longer in vivo and had more myocardiocytes survive than the experimental group of BM-MSCs transplanted. This was because the secretion of cytokine, which helps formation of blood vessels and cell growth, was maximized and delivered nutrients that promoted vascular regeneration and enhanced survival of the myocardiocytes.
The research team anticipated that this new method could be a breakthrough treatment of myocardial infarction as the implanted stem cells through HGF-eMSCs ultimately enhanced vascular regeneration and improved the myocardial infarction affected area.
“We can augment the function of adult stem cells approved by Ministry of Food and Drug Safety and FDA using this newly developed and promising 3D bioprinting technology with the engineered stem cells. It is our goal to develop a new concept of medicine for myocardial infarction in the near future,” says Prof. Jinah Jang, who led the research.
POSTECH began to develop medicine for cardiovascular diseases based on this newly developed bioprinting method with the research team from The Catholic University in 2017. Now, it is being tested in animals for efficacy evaluation with Chonnam National University. Also, the technology has been transferred to T&R Biofab, a company developing 3D printers, software, and bioinks to print cells.
The joint research team consisted of Prof. Jinah Jang and Dr. Sanskrita Das of POSTECH Creative IT Engineering, Seungman Jung of POSTECH School of Interdisciplinary Bioscience and Bioengineering, Prof. Hun-Jun Park, Mr. Bong-Woo Park, Soo-Hyun Jung of The Catholic University, and Prof. Kiwon Ban and his fellows from City University of Hong Kong.
The research was published in a recent issue of Science Advances. This study was supported by the National Research Foundation of Korea, Bio & Medical Technology Development Program, President’s Postdoc Fellowship grant, and ICT Consilience Creative Program grant funded by the Ministry of Science and ICT.
For more information, visit here .